Evolus 配当と自社株買い
配当金 基準チェック /06
Evolus配当金を支払った記録がありません。
主要情報
n/a
配当利回り
-0.09%
バイバック利回り
| 総株主利回り | -0.09% |
| 将来の配当利回り | n/a |
| 配当成長 | n/a |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | n/a |
| 配当性向 | n/a |
最近の配当と自社株買いの更新
更新なし
Recent updates
ナラティブの更新 • Jun 17
EOLS: International Filler Expansion Will Support Future Share Price Re Rating
Analysts currently keep their fair value estimate for Evolus steady at $14.67, indicating that the latest price target update reflects unchanged assumptions on discount rate, revenue growth, profit margin, and future P/E, rather than a shift in the underlying outlook. What’s in the News for Evolus Evolus plans to commercially launch its Estyme injectable hyaluronic acid gel collection in Europe on May 16, marking the company’s entry into the international dermal filler market.ナラティブの更新 • Jun 03
EOLS: International Filler Launch And Margin Reset Will Support Future Re Rating
Analysts now hold the price target for Evolus steady at $14.67. This reflects updated views on slightly higher revenue growth, a lower profit margin outlook, and a higher assumed future P/E multiple.ナラティブの更新 • May 11
EOLS: Updated Profitability Outlook Will Support Future Re Rating Potential
Analysts now hold Evolus at a steady fair value of $14.67, with adjusted assumptions that include a slightly higher discount rate, updated revenue growth and profit margin expectations, and a lower future P/E. Together these changes reshape how they see the stock's risk and reward profile.ナラティブの更新 • Apr 25
EOLS: Refined Assumptions Will Support Long Term Profitability Re Rating
Analysts have reduced their price target on Evolus by $4 to reflect slightly adjusted assumptions around long term revenue growth, profit margins and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts view the revised price target as still reflecting upside potential if Evolus delivers on its long term revenue goals, even with more conservative growth assumptions now included.ナラティブの更新 • Apr 10
EOLS: Guidance Reset Will Support Long Term Profitability Re Rating
Narrative Update on Evolus Analysts have trimmed their price targets on Evolus by $4 to $5 in recent reports, reflecting reactions to preliminary 2025 net revenues cited at the low end of expectations, tepid 2026 guidance, and a reset of the longer term outlook. Some still view this as management setting a cleaner stage for potential future success.ナラティブの更新 • Mar 27
EOLS: Guidance Reset And Margin Expansion Will Support 2028 Profitability Re Rating
Narrative Update on Evolus Analysts have trimmed their average price targets on Evolus by several dollars to reflect lower preliminary 2025 revenue indications, tepid 2026 guidance and a reset of longer term expectations, while still viewing the updated outlook as a potential setup for future success. Analyst Commentary Recent research has focused on what the lower preliminary 2025 revenue indications and more muted 2026 guidance mean for Evolus valuation and execution risk.ナラティブの更新 • Mar 11
EOLS: Guidance Reset And Margin Uplift Will Support 2028 Profitability Re Rating
Analysts have trimmed their average price target for Evolus by about $0.50 to reflect lower fair value and P/E assumptions after recent cuts to Street targets tied to softer preliminary 2025 revenues, cautious 2026 guidance and a reset of long term expectations. Analyst Commentary Recent Street research has centered on how Evolus is resetting expectations after preliminary 2025 net revenues came in at the low end of expectations and 2026 guidance struck a cautious tone.ナラティブの更新 • Feb 24
EOLS: Conservative Guidance Reset Will Support 2028 Profitability Re Rating
Analysts have trimmed their average price target on Evolus by about $4 to $17, citing recent guidance that came in at the low end of expectations, more cautious long term assumptions, and a reset in outlook that they still see as setting the stage for potential future success. Analyst Commentary Bullish Takeaways Bullish analysts view the reset in long term outlook as a clean starting point, which they think can make it easier for management to meet or exceed the new targets over time.ナラティブの更新 • Feb 09
EOLS: Guidance Reset And 2028 Outlook Will Support Future Re Rating
Analysts have trimmed their price targets on Evolus to about US$15.17 from US$17, reflecting more cautious assumptions around revenue growth, profit margins, and a higher future P/E after recent guidance updates and long term outlook resets. Analyst Commentary Recent Street research reflects a mix of caution and guarded optimism around Evolus after the latest guidance and long term outlook reset.
新しいナラティブ • Feb 02
Cash Pay Aesthetics Exposure Will Test Injectable Demand Yet Long Term Potential Remains
Catalysts About Evolus Evolus is a cash pay focused aesthetics company that markets neuromodulators and hyaluronic acid fillers to physicians and consumers. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Jan 26
EOLS: Guidance Reset And Long Term Outlook Will Support Future Re Rating
Narrative Update: Evolus Analysts have trimmed their fair value estimate for Evolus to US$17 from US$19, reflecting updated assumptions for slower revenue growth, slightly lower profit margins and a higher future P/E after recent cautious guidance and long term outlook resets. Analyst Commentary Recent Street research on Evolus has focused on lowered price targets and a reset of expectations following management’s preliminary 2025 revenue indication, 2026 guidance and long term outlook update.分析記事 • Jan 15
Lacklustre Performance Is Driving Evolus, Inc.'s (NASDAQ:EOLS) 30% Price Drop
Evolus, Inc. ( NASDAQ:EOLS ) shares have had a horrible month, losing 30% after a relatively good period beforehand...Seeking Alpha • Dec 17
Evolus: A Difficult 2025 Means I'm Downgrading Stock To 'Hold' For 2026
Summary Evolus (EOLS) is downgraded to 'Hold' as competitive pressures, cash constraints, and missed targets cloud its 2026 outlook. EOLS maintains long-term guidance of $700m revenue and 20% operating margin by 2028, but management will reassess targets early next year. Q3 revenues grew 13% YoY to $69m, but net losses persist and cash burn threatens liquidity by end-2026 if profitability is not achieved. Jeuveau gains market share and Evolysse shows early synergy, yet fierce competition and high SG&A expenses limit near-term upside. Read the full article on Seeking Alpha分析記事 • Aug 10
Analysts Just Slashed Their Evolus, Inc. (NASDAQ:EOLS) EPS Numbers
The latest analyst coverage could presage a bad day for Evolus, Inc. ( NASDAQ:EOLS ), with the analysts making...ナラティブの更新 • Aug 07
International Expansion And Pipeline Developments Will Reshape Aesthetics Markets
Evolus’s valuation outlook is slightly more cautious due to a higher discount rate, while future earnings expectations remain stable, resulting in an unchanged consensus price target of $23.57. What's in the News Evolus updated 2025 earnings guidance, projecting total net revenues between $295–$305 million (11%–15% growth over 2024) and increasing Evolysse injectable HA gels' revenue contribution to 10%–12%.分析記事 • May 30
Increases to CEO Compensation Might Be Put On Hold For Now at Evolus, Inc. (NASDAQ:EOLS)
Key Insights Evolus to hold its Annual General Meeting on 5th of June Salary of US$743.8k is part of CEO David...新しいナラティブ • May 29
International Expansion And New Offerings Will Transform Aesthetic Markets
International expansion and product diversification are expected to drive revenue growth, reduce earnings risk, and strengthen the company's competitive position.分析記事 • May 10
Analyst Estimates: Here's What Brokers Think Of Evolus, Inc. (NASDAQ:EOLS) After Its First-Quarter Report
The analysts might have been a bit too bullish on Evolus, Inc. ( NASDAQ:EOLS ), given that the company fell short of...Seeking Alpha • Apr 22
Evolus: Two-Product Aesthetics Company With A Competitive Edge
Summary Evolus is expanding from a single product, Jeuveau, to include Evolysse dermal fillers, targeting younger, image-conscious consumers and leveraging FDA-approved weight loss wrinkle labeling. Evolus achieved record revenue in 2024 with $266.3 million, marking five consecutive years of 30%-plus growth, and reached non-GAAP profitability ahead of schedule. The company's competitive edge includes a cash-pay model, strong digital marketing, loyalty programs, and proprietary COLD-X technology for dermal fillers. Despite growth, concerns remain about declining legacy business revenue and reliance on a single-source supply chain with Daewoong Pharmaceutical. Read the full article on Seeking Alpha分析記事 • Apr 09
Investors Give Evolus, Inc. (NASDAQ:EOLS) Shares A 31% Hiding
Evolus, Inc. ( NASDAQ:EOLS ) shareholders won't be pleased to see that the share price has had a very rough month...分析記事 • Jan 23
Evolus, Inc. (NASDAQ:EOLS) Soars 30% But It's A Story Of Risk Vs Reward
Evolus, Inc. ( NASDAQ:EOLS ) shareholders are no doubt pleased to see that the share price has bounced 30% in the last...Seeking Alpha • Jan 14
Evolus: Still Bullish, But Business Faces Tricky Challenges In '25
Summary I previously rated Evolus, Inc. stock a “Buy” due to its litigation settlement with AbbVie, strong revenue targets, and promising product performance. Despite positive updates, Evolus stock fell sharply, possibly due to market unpredictability and sector instability. Evolus' ambitious revenue targets and profitability projections face skepticism, but strong product performance and brand loyalty offer optimism. I maintain my “Buy” rating on EOLS, acknowledging industry challenges but recognizing Evolus' solid performance and potential for bullish Q4 earnings. Read the full article on Seeking Alpha分析記事 • Nov 13
Evolus, Inc. (NASDAQ:EOLS) Might Not Be As Mispriced As It Looks After Plunging 26%
Evolus, Inc. ( NASDAQ:EOLS ) shareholders won't be pleased to see that the share price has had a very rough month...分析記事 • Oct 22
Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Aug 02
Evolus Continues To Make Progress
Summary Today, we are circling back on aesthetic beauty concern Evolus, Inc., after the stock saw a 13% rise following Q2 results on Thursday. Evolus competes with Botox with Jeuveau, a botulinum toxin for glabellar lines, and is expanding with Evolysse™ dermal fillers. The company is delivering revenue growth in the mid-30s, continuing to take market share, and is marching toward profitability in FY2025. An updated analysis around Evolus follows in the paragraphs below. Read the full article on Seeking Alpha分析記事 • Aug 02
Evolus, Inc. (NASDAQ:EOLS) Looks Just Right With A 32% Price Jump
Evolus, Inc. ( NASDAQ:EOLS ) shares have had a really impressive month, gaining 32% after a shaky period beforehand...分析記事 • Jul 13
Evolus (NASDAQ:EOLS) Is Making Moderate Use Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • May 22
Evolus: Chiseling Away At The Aesthetic Market
Summary Evolus is a facial beauty company that specializes in aesthetic neurotoxins, with its flagship product being Jeuveau. The company is expanding its product portfolio by adding dermal fillers through exclusive agreements with Evolysse and Estyme. The market opportunity for Evolus is significant, with the neurotoxin market estimated at $3.5 billion and the dermal fillers market at $2.5 billion. Strong revenue growth, expanding product line, and imminent profitability present an attractive opportunity for a speculative small-cap stock that can potentially double. Read the full article on Seeking Alpha分析記事 • May 10
Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results
Evolus, Inc. ( NASDAQ:EOLS ) came out with its first-quarter results last week, and we wanted to see how the business...Seeking Alpha • Mar 20
Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028
Summary Evolus, a global performance beauty company, raised $60m in its IPO in 2018. Its first and only commercial product, Jeuveau, is an injectable botulinum toxin Type A product that has been approved in the US and most European territories. Evolus has settled a lawsuit with AbbVie and is focused on taking on Botox in the commercial markets. Management has guided for over $250m revenues in 2024, and over $700m by 2028 thanks to the launch of a new dermal filler range of products. Smartly marketed, effective, and growing market share, Jeuveau seems a strong product, and with support from the new range, I'd argue Evolus is well placed to grow its valuation and share price over the next several years. Read the full article on Seeking Alpha分析記事 • Mar 10
The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts
Shareholders might have noticed that Evolus, Inc. ( NASDAQ:EOLS ) filed its annual result this time last week. The...分析記事 • Jan 18
Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Evolus, Inc. ( NASDAQ:EOLS ) shares have continued their recent momentum with a 27% gain in the last month alone...分析記事 • Jan 18
Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up
Evolus, Inc. ( NASDAQ:EOLS ) shares have continued their recent momentum with a 27% gain in the last month alone...決済の安定と成長
配当データの取得
安定した配当: EOLSの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。
増加する配当: EOLSの配当金が増加しているかどうかを判断するにはデータが不十分です。
配当利回り対市場
| Evolus 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (EOLS) | n/a |
| 市場下位25% (US) | 1.3% |
| 市場トップ25% (US) | 4.1% |
| 業界平均 (Pharmaceuticals) | 1.9% |
| アナリスト予想 (EOLS) (最長3年) | n/a |
注目すべき配当: EOLSは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。
高配当: EOLSは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。
株主への利益配当
収益カバレッジ: EOLSの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。
株主配当金
キャッシュフローカバレッジ: EOLSが配当金を報告していないため、配当金の持続可能性を計算できません。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/01 11:22 |
| 終値 | 2026/07/01 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Evolus, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12
| アナリスト | 機関 |
|---|---|
| Navann Ty Dietschi | BNP Paribas |
| Michael Gorman | BTIG |
| Sam Eiber | BTIG |